Capricor Therapeutics (NASDAQ:CAPR) Trading Up 5.6% – Time to Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price rose 5.6% during trading on Monday . The company traded as high as $13.80 and last traded at $13.80. Approximately 460,344 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 1,196,887 shares. The stock had previously closed at $13.07.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CAPR shares. Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group increased their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald boosted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler began coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Performance

The firm has a market capitalization of $626.12 million, a price-to-earnings ratio of -12.99 and a beta of 3.98. The firm has a fifty day moving average price of $17.94 and a 200 day moving average price of $10.33.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently made changes to their positions in CAPR. Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the third quarter valued at about $3,806,000. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics during the third quarter worth $2,324,000. State Street Corp increased its position in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after buying an additional 111,291 shares in the last quarter. Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at about $426,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.